A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease

Inclusion Criteria Concurrent Medication: PER AMENDMENT 10/24/95: Allowed: * All antiretroviral agents and other medications except those listed under Exclusion - Concurrent Medications. * Didanosine. However, patients receiving both drugs (didanosine and ganciclovir) should be monitored for toxicity. * Amphotericin B is allowed but requires additional monitoring. Patients must have: * HIV infection. * CMV infection. * CD4 count \< 150 cells/mm3 or \< 15 percent AND/OR quiescent CMV disease. * NO loss of sight from CMV retinitis. * NO acute opportunistic infection. * Life expectancy at least to study completion. * Consent of parent or guardian. NOTE: * Infants \< 6 months of age at enrollment must have been \>= 36 weeks gestational age at birth. NOTE: * Patients may co-enroll in other ACTG protocols that do not involve the administration of disallowed medications. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Loss of sight in one eye for any reason, with evidence of CMV retinitis in the other eye. * Acute or chronic diarrhea that would affect absorption. * Clinical or laboratory toxicities of grade 3 or worse. Concurrent Medication: Excluded: * Foscarnet. * Acyclovir. * Interferon. * Myelotoxic agents for malignancy or other condition. * Other agents with anti-CMV activity. (NOTE: Enrollment of patients on IVIG must be discussed with protocol chair.) * Imipenem/cilastatin sodium. Prior Medication: Excluded within 30 days prior to study entry: * G-CSF or GM-CSF.